Streetbeat News

Price Targets

CTSO

EF Hutton analyst Jason Kolbert maintains a Buy rating on CytoSorbents (NASDAQ:CTSO) with a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 4:33 pm

PRVA

RBC Capital analyst Sean Dodge has reiterated an Outperform rating on Privia Health Group (NASDAQ:PRVA) and maintained a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 4:27 pm

SBUX

Citigroup analyst Jon Tower maintains a Neutral rating on Starbucks (NASDAQ:SBUX) but raises the price target from $82 to $98.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 4:21 pm

PANW

Palo Alto Networks shares are trading higher after Scotiabank and Citigroup raised their respective price targets on the stock.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 4:17 pm

HD

Home Depot shares are trading higher after UBS raised its price target on the stock from $400 to $425.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 4:16 pm

NEM

Financial giants have made significant bullish moves on Newmont (NYSE:NEM) options, with 23 unusual trades identified. The trades include 11 puts valued at $612,695 and 12 calls valued at $1,529,913. The price target for NEM ranges from $35.0 to $57.5. Currently, NEM is trading at $48.66, down 0.73%, with RSI indicators suggesting it may be overbought. An analyst from BMO Capital maintains an Outperform rating with a target price of $57.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 4:15 pm

HD

RBC Capital analyst Steven Shemesh maintains a Sector Perform rating on Home Depot (NYSE:HD) but lowers the price target from $377 to $363.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 4:15 pm

ATYR

RBC Capital analyst Gregory Renza has reiterated an Outperform rating on aTyr Pharma (NASDAQ:ATYR) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 4:13 pm

RKLB

Citigroup analyst Jason Gursky maintains a Buy rating on Rocket Lab USA (NASDAQ:RKLB) and raises the price target from $5.45 to $7.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 4:08 pm

SLRN

Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Acelyrin (NASDAQ:SLRN) but lowers the price target from $68 to $20.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 4:04 pm